Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 07h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results
12 août 2021 16h05 HE
|
Kronos Bio, Inc.
Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML) Unveiled SYK portfolio strategy and...
Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)
27 juil. 2021 08h00 HE
|
Kronos Bio, Inc.
Company intends to develop LANRA as a once-daily chronic treatment for genetically-defined AML patients Two Phase 1/2 clinical trials of LANRA are planned, with first trial to initiate in Q4 2021 ...
Kronos Bio Announces Participation in Upcoming Investor Conferences
26 mai 2021 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the...
Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today
25 mai 2021 08h00 HE
|
Kronos Bio, Inc.
Unveils development strategy for lanraplenib (LANRA), which will expand addressable patient population for SYK inhibitor portfolio in acute myeloid leukemia (AML); plans to initiate two Phase 1/2...
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day
11 mai 2021 16h05 HE
|
Kronos Bio, Inc.
Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and differentiated drug discovery platform Preclinical data for KB-0742...
Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference
06 mai 2021 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021
10 avr. 2021 08h30 HE
|
Kronos Bio, Inc.
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer anti-tumor activity, including in tumors exposed to prior lines of therapy, seen with intermittent...
Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.
31 mars 2021 11h25 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in...
Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors
26 mars 2021 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...